依匹哌唑（OPC-34712）是一种口服有效的非典型抗精神病药物，作为5-HT1A（Ki=0.12 nM）和多巴胺D2L受体（Ki=0.3 nM）的部分激动剂，以及5-HT2A受体（Ki=0.47 nM）的拮抗剂，同时对去甲肾上腺素能受体α1B（Ki=0.17 nM）和α2C（Ki=0.59 nM）也表现出强效拮抗活性。
|
英文别名 (English Synonym) |
Brexpiprazole |
|
中文名称 (Chinese Name) |
依匹哌唑 |
|
靶点 (Target) |
Dopamine Receptor |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
913611-97-9 |
|
分子式 (Formula) |
C25H27N3O2S |
|
分子量 (Molecular Weight) |
433.57 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11. doi: 10.1016/j.euroneuro.2015.01.014. Epub 2015 Feb 7. PMID: 25687838.[2]Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64. doi: 10.1016/j.euroneuro.2014.12.014. Epub 2015 Jan 5. PMID: 25600995.
